SAN DIEGO, CA--(Marketwired - Mar 12, 2014) - Aegis Therapeutics LLC's Intravail® technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral ...
Dauntless Pharmaceuticals, Inc. (Dauntless), a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC (Aegis) today announced a licensing agreement ...
SAN DIEGO, CA--(Marketwire - Sep 24, 2012) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,268,791 providing fast acting formulations for triptans, a class of drugs ...
On July 19, 2017, Opiant Pharmaceuticals Inc. (OPNT) announced results from a Phase 1 study of OPNT002, an intranasally (IN) administered formulation of the opioid antagonist naltrexone hydrochloride.
SANTA MONICA, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today ...
Company is targeting medications that together made over $1 billion in sales annually. Dr. Reddy’s Laboratories negotiated access to Aegis Therapeutics’ Intravail® drug-delivery technology for use ...
SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Neurelis, Inc. announced today that its Intravail® licensing partner, ARS Pharmaceuticals, Inc., received Fast Track designation from the FDA for ARS-1, its ...
SAN DIEGO, Dec. 8, 2022 /PRNewswire/ -- ARS Pharmaceuticals, Inc., announced that the U.S. Food & Drug Administration (FDA) has accepted its New Drug Application (NDA) for neffy (previously referred ...
Company is targeting medications that together made over $1 billion in sales annually. Dr. Reddy’s Laboratories negotiated access to Aegis Therapeutics’ Intravail® drug-delivery technology for use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results